An open label 2x2 factorial randomized trial is planned to determine the difference in mean
hemostasis time between low dose heparin (LD) i.e between 2000-3000 IU and standard dose
heparin (SD) i.e. 5000 IU with or without catecholamine chitosan-based pad (InnoSEAL
hemostatic pad, InnoTherapy, Inc. S Korea) used in conjunction with TRB (InnoSEAL+TRB
[I+TRB]) among patients who are undergoing left heart cath at Tabba Heart Institute.
Secondary objectives include testing the difference in radial artery occlusion (RAO), and
hematoma (III, IV grade) and composite outcome (RAO+hematoma).